Nocturnal Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs

Stephen A. Brunton, MD

Disclosures
In This Article

Abstract

Background: Nocturnal hypoglycemia may be the most common type of hypoglycemia in individuals with diabetes using insulin and is particularly worrisome because it often goes undetected and may lead to unconsciousness and even death in severe cases.
Objectives: The prevalence, causes, and consequences of nocturnal hypoglycemia as well as detection and prevention strategies are reviewed, including the use of long-acting insulin analogs, which offer more physiologic and predictable time-action profiles than traditional human basal insulin.
Data Sources: A total of 307 publications (151 PubMed; 104 Adis; 52 BIOSIS) were reviewed.
Review Methods: Relevant trials were found by searching for "(detemir OR glargine) AND nocturnal AND (hypoglycemia OR hypoglycaemia) AND diabetes." To capture trials that may not have specified "nocturnal" in the title or abstract text but still reported nocturnal hypoglycemia data, a supplemental search of PubMed using "(detemir OR glargine) AND (nocturnal OR hypoglycemia OR hypoglycaemia) AND diabetes" was undertaken.
Results: A review of these trials found that patients with type 1 and type 2 diabetes mellitus have a lower risk for nocturnal hypoglycemia when receiving long-acting insulin analogs (insulin detemir or insulin glargine), provided that glycemic control is comparable to that provided by traditional human basal insulin. Long-acting insulin analogs may be the best option to provide basal insulin coverage in patients who do not choose or require continuous subcutaneous insulin infusion.
Conclusions: Randomized clinical trials suggest that the long-acting insulin analogs are associated with a lower risk for nocturnal hypoglycemia than neutral protamine Hagedorn without sacrificing glycemic control.


Readers are encouraged to respond to the author at Sbrunton@pceconsortium.org or to Paul Blumenthal, MD, Deputy Editor of MedGenMed, for the editor's eyes only or for possible publication via email: pblumen@stanford.edu

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....